A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.
Abstract
Lipedema is a chronic disease of subcutaneous adipose tissue that predominantly affects women and is frequently associated with endocrinopathies such as insulin resistance and obesity. Its pathogenesis is still unclear, and treatment, which requires a multi-disciplinary approach, is prolonged over time and is not always effective. There is currently no drug treatment available for this disease. Five different cases of women with lipedema and insulin resistance, treated with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and once-weekly exenatide, in association or not with lifestyle changes (diet or physical activity) for 3 to 6 months are described. Changes in anthropometric parameters, symptoms, clinical findings and the thickness of superficial adipose tissue measured by ultrasound were evaluated. Treatment with exenatide, whether combined with a change in diet or physical activity, resulted in a reduction in the characteristic symptoms of lipedema, in pain evoked by pinching the adipose tissue fold and in the thickness of subcutaneous adipose tissue at the levels of the lower limbs, abdomen and upper limbs. In four out of five cases, a reduction in body weight was observed, particularly during the first three months of treatment and in cases with greater metabolic impairment. Clinical, instrumental and subjective improvements were also observed in cases where there was no reduction in body weight and in patients who had previously undergone lower limb liposuction. The improvement in symptoms and clinical signs of lipedema, in addition to the reduction in adipose tissue in patients with lipedema and insulin resistance with exenatide, suggests a novel pharmacological approach to the disease, which can be combined with other conservative and surgical treatments to promote weight reduction. These results also highlight the association of this disease with metabolic alterations and the fundamental role of an accurate diagnosis followed by the treatment of comorbidities and excess weight in these patients.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | subcutaneous
|
피하조직 | dict | 2 | |
| 시술 | liposuction
|
지방흡입 | dict | 1 | |
| 해부 | lower limb
|
scispacy | 1 | ||
| 해부 | subcutaneous adipose tissue
|
scispacy | 1 | ||
| 해부 | superficial adipose tissue
|
scispacy | 1 | ||
| 해부 | adipose tissue
|
scispacy | 1 | ||
| 해부 | lower limbs
|
scispacy | 1 | ||
| 해부 | upper limbs
|
scispacy | 1 | ||
| 해부 | body
|
scispacy | 1 | ||
| 합병증 | Lipedema
|
scispacy | 1 | ||
| 합병증 | abdomen
|
scispacy | 1 | ||
| 약물 | Exenatide
|
C0167117
exenatide
|
scispacy | 1 | |
| 약물 | once-weekly
|
scispacy | 1 | ||
| 질환 | Lipedema
|
C0398370
Lipedema
|
scispacy | 1 | |
| 질환 | endocrinopathies
|
C0014130
Endocrine System Diseases
|
scispacy | 1 | |
| 질환 | obesity
|
C0028754
Obesity
|
scispacy | 1 | |
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | metabolic alterations
|
scispacy | 1 | ||
| 질환 | Case
|
scispacy | 1 | ||
| 질환 | disease
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | women
|
scispacy | 1 | ||
| 기타 | insulin
|
scispacy | 1 | ||
| 기타 | GLP-1
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.
- Hyperhidrosis: Prevalence, Diagnosis, and Stepwise Treatment.
- Application of the SCIA-Pure Skin Perforator Flap in Bilateral Upper Eyelid Reconstruction: A Case Report and Review of the Literature.
- Venous thromboembolism prophylaxis regimen for patients undergoing deep inferior epigastric perforator flap breast reconstruction.
- Immediate one-stage subcutaneous breast reconstruction without ADM: A single-center 6-year experience.